>

>

Publications and presentations

PUBLICATIONS AND PresentationS

Discover the main highlights of our industry in our latest publications.

Quick links

Presentation

Plasma Saves Lives: Addressing the COVID-19 Pandemic

PlasmaVigilance: Source Plasma Donor Hemovigilance Activities and Results

Europe's Need for More Plasma – Event Report

PPTA 2022 Annual Report

Publication

Key Economic & Value Considerations in the US
Market for PPTs

Key Economic & Value Considerations for PDMPs
in Europe

Plasma donation: New thinking to serve Europe’s patients -- Practices & approaches for countries

Nanofiltration as a robust method contributing to viral safety of plasma-derived therapeutics

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

Letter to the editor regarding PPTA study in Transfusion

Letter to the editor regarding PPTA study in Transfusion

https://www.google.com/url?sa=i&source=web&rct=j&url=https://iwebb.carterbloodcare.org/Memo/DownloadFile/9102&ved=2ahUKEwiNgKr9nYmSAxVAGVkFHZjgPOAQy_kOegQIARAC&opi=89978449&cd&psig=AOvVaw1oA-5lzUOqmS1fb5mh_w2N&ust=1768418382569000

Letter to the editor regarding PPTA study in Transfusion

Letter to the editor regarding PPTA study in Transfusion

https://www.google.com/url?sa=i&source=web&rct=j&url=https://iwebb.carterbloodcare.org/Memo/DownloadFile/9102&ved=2ahUKEwiNgKr9nYmSAxVAGVkFHZjgPOAQy_kOegQIARAC&opi=89978449&cd&psig=AOvVaw1oA-5lzUOqmS1fb5mh_w2N&ust=1768418382569000

Effects of donation frequency on U.S. source plasma donor health

Effects of donation frequency on U.S. source plasma donor health

https://onlinelibrary.wiley.com/doi/10.1111/trf.17523

Effects of donation frequency on U.S. source plasma donor health

Effects of donation frequency on U.S. source plasma donor health

https://onlinelibrary.wiley.com/doi/10.1111/trf.17523

PPTA’s Plasmavigilance Program: Adverse events among U.S. Source plasma donors

PPTA’s Plasmavigilance Program: Adverse events among U.S. Source plasma donors

https://plasmaprotein.sharepoint.com/sites/COMMS/cd/Forms/AllItems.aspx?id=%2Fsites%2FCOMMS%2Fcd%2FSource%20Magazine%2FPublication%20%28permanent%29%2FSource%5FSpring%202022%2Epdf&parent=%2Fsites%2FCOMMS%2Fcd%2FSource%20Magazine%2FPublication%20%28permanent%29&p=true&ga=1

PPTA’s Plasmavigilance Program: Adverse events among U.S. Source plasma donors

PPTA’s Plasmavigilance Program: Adverse events among U.S. Source plasma donors

https://plasmaprotein.sharepoint.com/sites/COMMS/cd/Forms/AllItems.aspx?id=%2Fsites%2FCOMMS%2Fcd%2FSource%20Magazine%2FPublication%20%28permanent%29%2FSource%5FSpring%202022%2Epdf&parent=%2Fsites%2FCOMMS%2Fcd%2FSource%20Magazine%2FPublication%20%28permanent%29&p=true&ga=1

Plasmavigilance-Adverse events among US Source plasma donors

Source plasma (SP) is the primary starting material for 87% of plasma-derived medicinal products globally. Plasmavigilance is a program designed to collect, analyze, and monitor donor adverse events (AEs) across the SP collection industry.

Plasmavigilance-Adverse events among US Source plasma donors

https://pubmed.ncbi.nlm.nih.gov/34390267/

Plasmavigilance-Adverse events among US Source plasma donors

Source plasma (SP) is the primary starting material for 87% of plasma-derived medicinal products globally. Plasmavigilance is a program designed to collect, analyze, and monitor donor adverse events (AEs) across the SP collection industry.

Plasmavigilance-Adverse events among US Source plasma donors

https://pubmed.ncbi.nlm.nih.gov/34390267/

No results found